Acelyrin, Inc. (NASDAQ:SLRN - Get Free Report) insider Amar Murugan sold 3,913 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $2.74, for a total transaction of $10,721.62. Following the completion of the transaction, the insider now directly owns 121,587 shares in the company, valued at approximately $333,148.38. This represents a 3.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Acelyrin Stock Performance
Shares of NASDAQ SLRN traded down $0.02 during midday trading on Friday, reaching $2.75. 1,392,082 shares of the company's stock were exchanged, compared to its average volume of 1,209,203. Acelyrin, Inc. has a 52-week low of $1.85 and a 52-week high of $7.30. The business's fifty day moving average price is $2.29 and its two-hundred day moving average price is $3.81. The stock has a market capitalization of $275.90 million, a PE ratio of -1.12 and a beta of 1.25.
Acelyrin (NASDAQ:SLRN - Get Free Report) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.07. Analysts predict that Acelyrin, Inc. will post -2.53 earnings per share for the current fiscal year.
Institutional Trading of Acelyrin
A number of hedge funds and other institutional investors have recently made changes to their positions in SLRN. T. Rowe Price Investment Management Inc. grew its holdings in Acelyrin by 23.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,872,124 shares of the company's stock worth $40,419,000 after acquiring an additional 2,440,278 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in Acelyrin in the fourth quarter worth about $4,760,000. ADAR1 Capital Management LLC grew its stake in Acelyrin by 731.7% in the fourth quarter. ADAR1 Capital Management LLC now owns 444,967 shares of the company's stock worth $1,397,000 after purchasing an additional 391,467 shares in the last quarter. Geode Capital Management LLC increased its holdings in Acelyrin by 30.8% in the third quarter. Geode Capital Management LLC now owns 1,651,614 shares of the company's stock valued at $8,144,000 after buying an additional 388,631 shares during the last quarter. Finally, Stempoint Capital LP raised its stake in Acelyrin by 29.4% during the fourth quarter. Stempoint Capital LP now owns 1,704,825 shares of the company's stock valued at $5,353,000 after buying an additional 386,971 shares in the last quarter. Institutional investors own 87.31% of the company's stock.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on the company. Wells Fargo & Company lowered their price target on Acelyrin from $15.00 to $13.00 and set an "overweight" rating for the company in a report on Wednesday, December 11th. Citigroup lowered their target price on Acelyrin from $6.00 to $3.00 and set a "neutral" rating for the company in a research note on Tuesday, January 7th. Finally, HC Wainwright reduced their price target on Acelyrin from $8.00 to $6.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $9.60.
Read Our Latest Research Report on SLRN
About Acelyrin
(
Get Free Report)
Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
Further Reading
Before you consider Acelyrin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acelyrin wasn't on the list.
While Acelyrin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
